# Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

> **NCT04590781** · PHASE1,PHASE2 · TERMINATED · sponsor: **Xencor, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Merkel Cell Carcinoma
- Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** XmAb18087
- **DRUG:** XmAb18087 ± Pembrolizumab

## Key facts

- **NCT ID:** NCT04590781
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-10
- **Primary completion:** 2022-03-24
- **Final completion:** 2022-03-24
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The study has been terminated early by the sponsor due to business decision.
- **Last updated:** 2023-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04590781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04590781, "Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04590781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*